EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudie

Incremental Value of Transrectal Ultrasound Target Visibility Beyond Clinical and MRI Variables for Predicting Biopsy-Detected Clinically Significant Prostate Cancer: Temporal and External Validation

Xiubin Tang, Ming Chen, Youhai Wu, Hanzong Lin, Chunrong Zhong, Xiao Yang

European Journal of Radiology · 2026

DOI: 10.1016/j.ejrad.2026.113255 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Radiology, 2026. Verfasst von Xiubin Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University (Zhangzhou Municipal Hospital of Fujian Province), No. 59 Shengl…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Image-Guided Biopsy, Ultrasonography, Interventional. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China, Fujian Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To determine whether three-level transrectal ultrasound (TRUS) target visibility adds predictive information beyond clinical and magnetic resonance imaging (MRI) variables for patient-level biopsy-detected clinically significant prostate cancer (csPCa). MATERIALS AND METHODS: This retrospective two-center study included 2,700 men undergoing cognitive transperineal biopsy. Center A provided development (n = 1,642) and temporal validation (n = 565) cohorts, and Center B provided external validation (n = 493). Gradient-boosting models were evaluated. TRUS visibility was retrospectively classified from contemporaneous biopsy-planning materials by readers blinded to pathology. Performance was assessed using AUC, average precision (AP), Brier score, quantitative calibration, exploratory decision-curve analysis, and interobserver reproducibility. RESULTS: Adding visibility to the Clinical-MRI model produced modest but consistent improvement. In temporal validation, ΔAUC was 0.039 (95 % CI, 0.021-0.058), ΔAP 0.074 (0.034-0.116), and ΔBrier score - 0.016 (-0.023 to - 0.009); corresponding external differences were 0.023 (0.009-0.037), 0.045 (0.014-0.075), and - 0.016 (-0.023 to - 0.008). Calibration intercept/slope for the visibility model were - 0.074/1.160 temporally and 0.316/1.304 externally. Visibility-specific csPCa gradients were preserved in both validation cohorts, with no evidence of center-by-visibility heterogeneity. Interobserver agreement was high (linear-weighted Cohen's κ = 0.82). CONCLUSION: TRUS target visibility provides modest incremental post-TRUS risk information beyond clinical and MRI variables. Because csPCa was defined at the patient level from targeted or systematic cores, the observed association cannot distinguish lesion biology from improved localization or sampling. Its potential role is risk refinement and sampling assistance, not biopsy avoidance or evidence of causal benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMagnetic Resonance ImagingImage-Guided BiopsyUltrasonography, InterventionalHumansMaleReproducibility of ResultsSensitivity and SpecificityAgedMiddle AgedRetrospective StudiesClinical RelevanceUltrasonographyObserver Variation

Stichwörter der Autor:innen

Cognitive biopsyMagnetic resonance imagingPrediction modelProstate cancerTransrectal ultrasound

Autor:innen und Institutionen

  • Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University (Zhangzhou Municipal Hospital of Fujian Province), No. 59 Shengli West Road, Xiangcheng District, Zhangzhou, Fujian 363000, China.
  • Department of Ultrasound, The Second Affiliated Hospital of Fujian Medical University, No. 34 Zhongshan North Road, Licheng District, Quanzhou, Fujian 362000, China.
  • Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University (Zhangzhou Municipal Hospital of Fujian Province), No. 59 Shengli West Road, Xiangcheng District, Zhangzhou, Fujian 363000, China; Dep…

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • National Key Research and Development Program of China
  • Fujian Medical University

Zitieren

APA

Tang, X., Chen, M., Wu, Y., Lin, H., Zhong, C., & Yang, X. (2026). Incremental Value of Transrectal Ultrasound Target Visibility Beyond Clinical and MRI Variables for Predicting Biopsy-Detected Clinically Significant Prostate Cancer: Temporal and External Validation. European Journal of Radiology. https://doi.org/10.1016/j.ejrad.2026.113255

Vancouver

Tang X, Chen M, Wu Y, Lin H, Zhong C, Yang X. Incremental Value of Transrectal Ultrasound Target Visibility Beyond Clinical and MRI Variables for Predicting Biopsy-Detected Clinically Significant Prostate Cancer: Temporal and External Validation. European Journal of Radiology. 2026. doi:10.1016/j.ejrad.2026.113255

BibTeX
@article{Tang2026,
  author = {Tang, Xiubin and Chen, Ming and Wu, Youhai and Lin, Hanzong and Zhong, Chunrong and Yang, Xiao},
  title = {Incremental Value of Transrectal Ultrasound Target Visibility Beyond Clinical and MRI Variables for Predicting Biopsy-Detected Clinically Significant Prostate Cancer: Temporal and External Validation},
  journal = {European Journal of Radiology},
  year = {2026},
  doi = {10.1016/j.ejrad.2026.113255}
}
Kostenlos starten →